NO993979L - FremgangsmÕte for Õ forhindre og forsinke starten pÕ Alzheimer's sykdom og sammensetning derfor - Google Patents

FremgangsmÕte for Õ forhindre og forsinke starten pÕ Alzheimer's sykdom og sammensetning derfor

Info

Publication number
NO993979L
NO993979L NO993979A NO993979A NO993979L NO 993979 L NO993979 L NO 993979L NO 993979 A NO993979 A NO 993979A NO 993979 A NO993979 A NO 993979A NO 993979 L NO993979 L NO 993979L
Authority
NO
Norway
Prior art keywords
alzheimer
onset
disease
composition
procedures
Prior art date
Application number
NO993979A
Other languages
English (en)
Norwegian (no)
Other versions
NO993979D0 (no
Inventor
Egon Novak
Original Assignee
Forbes Medi Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forbes Medi Tech Inc filed Critical Forbes Medi Tech Inc
Publication of NO993979D0 publication Critical patent/NO993979D0/no
Publication of NO993979L publication Critical patent/NO993979L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO993979A 1997-12-18 1999-08-18 FremgangsmÕte for Õ forhindre og forsinke starten pÕ Alzheimer's sykdom og sammensetning derfor NO993979L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/993,901 US5985936A (en) 1997-12-18 1997-12-18 Method of preventing and delaying onset of Alzheimer's disease and composition therefor
PCT/CA1998/001147 WO1999032097A2 (en) 1997-12-18 1998-12-18 Phytosterol composition for preventing alzheimer's disease

Publications (2)

Publication Number Publication Date
NO993979D0 NO993979D0 (no) 1999-08-18
NO993979L true NO993979L (no) 1999-10-13

Family

ID=25540052

Family Applications (1)

Application Number Title Priority Date Filing Date
NO993979A NO993979L (no) 1997-12-18 1999-08-18 FremgangsmÕte for Õ forhindre og forsinke starten pÕ Alzheimer's sykdom og sammensetning derfor

Country Status (18)

Country Link
US (1) US5985936A (ro)
EP (1) EP0967982A2 (ro)
CN (1) CN1252724A (ro)
AU (1) AU1656099A (ro)
BG (1) BG103740A (ro)
BR (1) BR9807577A (ro)
CA (1) CA2281710A1 (ro)
EE (1) EE9900354A (ro)
GE (1) GEP20022783B (ro)
HU (1) HUP0100737A3 (ro)
LT (1) LT4801B (ro)
LV (1) LV12438B (ro)
MD (1) MD1920F2 (ro)
NO (1) NO993979L (ro)
PL (1) PL335421A1 (ro)
RU (1) RU2173151C2 (ro)
SK (1) SK112999A3 (ro)
WO (1) WO1999032097A2 (ro)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8679534B2 (en) * 1997-12-12 2014-03-25 Andrx Labs, Llc HMG-CoA reductase inhibitor extended release formulation
AU780624B2 (en) * 1999-11-04 2005-04-07 Andrx Corporation Method of treating amyloid beta precursor disorders
US20020107173A1 (en) * 1999-11-04 2002-08-08 Lawrence Friedhoff Method of treating amyloid beta precursor disorders
MXPA02009956A (es) 2000-04-14 2003-02-12 Mars Inc Composiciones y metodos para mejorar la salud vascular.
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US20030013692A1 (en) * 2001-01-19 2003-01-16 Gullans Steven R. Methods of treating neurological disorders
RS20100015A (sr) 2001-01-26 2010-12-31 Schering Corporation Kombinacija aktivatora receptora aktiviranog peroksizom- proliferatorom (ppar) fenofibrata sa inhibitorom apsorpcije sterola ezetimibom za vaskularne indikacije
HU230435B1 (hu) 2001-01-26 2016-06-28 Merck Sharp & Dohme Corp Szubsztituált azetidinon vegyületek alkalmazása szitoszterinémia kezelésére
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US20040106124A1 (en) * 2001-02-12 2004-06-03 Murphy Greer M. Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4 and for improving the terapeutic response of humans having major depression and carrying the gene for apolipoprotein e4
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
CA2460340C (en) 2001-09-21 2011-02-15 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
DE10154221A1 (de) * 2001-11-07 2003-05-15 Max Delbrueck Centrum Mittel zur Behandlung von Läsionen des Nervensystems
MXPA05004811A (es) 2002-11-06 2005-07-22 Schering Corp Inhibidores de absorcion de colesterol para el tratamiento de trastornos autoinmunes.
FR2848452B1 (fr) * 2002-12-12 2007-04-06 Aventis Pharma Sa Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
UA87453C2 (ru) * 2003-02-01 2009-07-27 Вайет Применения фрагмента ав для лечения болезни альцгеймера
CA2517571C (en) 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
MXPA05009501A (es) 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
MXPA05009502A (es) * 2003-03-07 2005-10-18 Schering Corp Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
GB0513881D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
US20080182801A1 (en) * 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
EP1743036A4 (en) * 2004-01-22 2008-07-02 Genaissance Pharmaceuticals APOE GENERAL MARKERS RELATED TO ALZHEIMER IN THE FIRST EARLY PERIOD
CA2587985C (en) * 2004-11-24 2016-05-10 Neopro Labs, Llc Peptides for use in treatment in fever or pain
GB0512726D0 (en) * 2005-06-22 2005-07-27 Btg Int Ltd Multiple sclerosis therapy and diagnosis
GB0513888D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
GB0513883D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis
RU2297860C1 (ru) * 2006-02-07 2007-04-27 Иван Васильевич Максимович Способ эндоваскулярного лечения болезни альцгеймера
BRPI0909378A2 (pt) * 2008-03-27 2015-10-06 Evotec Neurosciences Gmbh métodos para tratar distúrbios usando antagonista seletivo de nmda subtipo nr2b
WO2010104375A1 (en) * 2009-03-12 2010-09-16 N.V. Nutricia Stigmasterol for the treatment of alzheimer's disease
US9011937B2 (en) * 2010-11-22 2015-04-21 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
US10383886B2 (en) 2010-01-11 2019-08-20 Phoenix Biotechnology, Inc. Method of treating neurological conditions with oleandrin
US10307450B2 (en) 2010-01-11 2019-06-04 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
US9376481B2 (en) 2011-04-26 2016-06-28 The Regents Of The University Of California Methods of promoting CNS neuronal repair by inhibiting LRP-1
CN102813659A (zh) * 2012-08-21 2012-12-12 贵阳中医学院 20α-二甲胺基- 2α-羟基-3β-惕洛酰胺基-5α-孕甾烷的用途
WO2015123618A1 (en) * 2014-02-14 2015-08-20 Arizona Board Of Regents For The University Of Arizona Method for increasing bcl2 gene expression
US10702567B2 (en) 2016-09-14 2020-07-07 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
US10596186B2 (en) 2016-09-14 2020-03-24 Phoenix Biotechnology, Inc. Method and compositions for treating viral infections
US11331291B2 (en) 2017-09-14 2022-05-17 Phoenix Biotechnology, Inc. Method of and improved composition for treating triterpene-responsive conditions, diseases or disorders
EP3681477A4 (en) 2017-09-14 2021-06-09 Phoenix Biotechnology, Inc. PROCEDURES AND IMPROVED COMPOSITION FOR TREATMENT OF TREITERPEN RESPONSIBLE CONDITIONS, DISEASES, OR DISORDERS
WO2021130002A1 (en) 2019-12-24 2021-07-01 Folium Biosciences Europe B.V. Food supplement for alzheimer
EP3842039A1 (en) * 2019-12-24 2021-06-30 Folium Biosciences Europe B.V. Food supplement comprising cannbinoids and phytosterols for alzheimer
US11806359B2 (en) 2020-03-31 2023-11-07 Phoenix Biotechnology, Inc. Method and compositions for treating Coronavirus infection
CU24748B1 (es) 2022-11-04 2025-04-04 Centro Nac De Biopreparados Nutracéutico para la prevención y tratamiento del deterioro cognitivo

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2057531C1 (ru) * 1986-07-01 1996-04-10 Всероссийский научный центр по безопасности биологически активных веществ Средство для стимуляции обучения и памяти
IT1203515B (it) * 1987-02-26 1989-02-15 Indena Spa Complessi di saponine con fosfolipidi e composizioni farmaceutiche e cosmetiche che li contengono
WO1990014087A1 (en) * 1989-05-17 1990-11-29 Pfizer Inc. 2-piperidino-1-alkanol derivatives as antiischemic agents
JP2862374B2 (ja) * 1992-12-17 1999-03-03 フアイザー・インコーポレイテツド Ｃｒｆアンタゴニスト活性を有するピラゾール及びピラゾロピリミジン
AU6274394A (en) * 1993-02-23 1994-09-14 Pharmakon Usa, Inc. Therapeutic herbal composition
US5589182A (en) * 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
EP0783514B2 (en) * 1994-09-29 2007-08-01 The University Of British Columbia Sterol compositions from pulping soap
CN1179903A (zh) * 1996-10-09 1998-04-29 李辉 营养丝米粉
WO1998051302A1 (en) * 1997-05-15 1998-11-19 University Of Washington Composition and methods for treating alzheimer's disease and other amyloidoses

Also Published As

Publication number Publication date
SK112999A3 (en) 2001-11-06
EE9900354A (et) 2000-02-15
RU2173151C2 (ru) 2001-09-10
EP0967982A2 (en) 2000-01-05
WO1999032097A2 (en) 1999-07-01
LT4801B (lt) 2001-06-25
MD990262A (ro) 2000-06-30
CN1252724A (zh) 2000-05-10
BG103740A (en) 2000-05-31
LT99114A (lt) 2001-01-25
AU1656099A (en) 1999-07-12
WO1999032097A3 (en) 1999-09-02
LV12438A (en) 2000-03-20
PL335421A1 (en) 2000-04-25
MD1920F2 (ro) 2002-05-31
CA2281710A1 (en) 1999-07-01
LV12438B (en) 2000-09-20
US5985936A (en) 1999-11-16
NO993979D0 (no) 1999-08-18
HUP0100737A3 (en) 2002-07-29
HUP0100737A2 (hu) 2001-09-28
GEP20022783B (en) 2002-09-25
BR9807577A (pt) 2001-08-07

Similar Documents

Publication Publication Date Title
NO993979L (no) FremgangsmÕte for Õ forhindre og forsinke starten pÕ Alzheimer's sykdom og sammensetning derfor
TR200101481T2 (tr) Doğal bitkisel zaruri yağlar kullanan kanser tedavi kompozisyonu ve yöntemi.
IL130931A0 (en) Small molecules useful in the treatment of inflammatory disease
ATE324872T1 (de) Orale pharmazeutische zusammensetzung mit verzögerter wirkstofffreigabe von protonenpumpen- hemmern
IS4972A (is) Notkun klóbindiefnisins klíókínól við að framleiða lyfjablöndu til að meðhöndla Alzheimers-sjúkdóm
ES2192227T3 (es) Composiciones farmaceuticas orales con liberacion retardada de inhibidores reversibles de las bombas de protones.
BR9713866A (pt) Composição farmacéutica
NO2007004I1 (no) Mycofenolsyre = (E)-6-(1,3-dihydro-4-hydroksy-6-metoksy-7-metyl-3-oksajsobenzofuran-5-yl)-4-, metylheks-4-ensyre
NO20101067L (no) Hydroksymatairesinol i forhindring av kreft
NO971206D0 (no) Forlenget-frigjöringsformulering
ATE197897T1 (de) Hautpflegemittel
NO951613L (no) Ikke-peptidyl tachykinin reseptorantagonister
DK1303632T3 (da) Galactomannan-oligosaccharid og fremgangsmåde til fremstilling samt anvendelse heraf
DK0998287T3 (da) Anvendelse af levobupivacain
BR9911040A (pt) 2-fenil-1-[4-(2-aminoetóxi)-benzil]-indol em combinação com estrogêneos
ATE272628T1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
DK1073456T3 (da) Anvendelse af osteoprotegerin til forebyggelse og behandling af kardiovaskulære sygdomme
FR2818148B1 (fr) Composition,notamment cosmetique, renfermant, la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un isoflavonoide
WO2002072021A3 (en) Agents and methods for the prevention of initial onset and recurrence of existing cancers
BG102660A (en) Combined pharmaceutical preparation of lhrh-analogues and antiesterogens for the treatment of gynaecological disorders
BR9506389B1 (pt) composto de silìcio, e, composição dietética, cosmética e terapêutica.
BG105471A (bg) Метод за предотвратяване или забавяне на необходимостта от катетър-основан на реваскуларизация
IL143516A0 (en) COMPOUNDS AND METHODS FOR MODULATING ACTIVATION OF NF-k-B
NO20005981L (no) Anvendelse av 2-hydroksy-4-trifluorbenzosyrederivater som inhibitorer av aktivering av den nukleære transkripsjonsfaktor NF- <kappa>B
WO2000030425A3 (en) Method of using pon-1 to decrease atheroma formation

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application